Cough Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Alerts
• Clinical Trials
• Forums

Cough Reduction in Patients With Refractory Chronic Cough Following Administration of NAL ER Versus Placebo
Condition:   Refractory Chronic Cough Interventions:   Drug: Nalbuphine Hydrochloride;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in IPF With Nalbuphine ER
Condition:   Idiopathic Pulmonary Fibrosis Interventions:   Drug: nalbuphine ER;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in Patients With Refractory Chronic Cough Following Administration of NAL ER Versus Placebo
Condition:   Refractory Chronic Cough Interventions:   Drug: Nalbuphine Hydrochloride;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in IPF With Nalbuphine ER
Condition:   Idiopathic Pulmonary Fibrosis Interventions:   Drug: nalbuphine ER;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in Patients With Refractory Chronic Cough Following Administration of NAL ER Versus Placebo
Condition:   Refractory Chronic Cough Interventions:   Drug: Nalbuphine Hydrochloride;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in IPF With Nalbuphine ER
Condition:   Idiopathic Pulmonary Fibrosis Interventions:   Drug: nalbuphine ER;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in Patients With Refractory Chronic Cough Following Administration of NAL ER Versus Placebo
Condition:   Refractory Chronic Cough Interventions:   Drug: Nalbuphine Hydrochloride;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in IPF With Nalbuphine ER
Condition:   Idiopathic Pulmonary Fibrosis Interventions:   Drug: nalbuphine ER;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Cough Reduction in Patients With Refractory Chronic Cough Following Administration of NAL ER Versus Placebo
Condition:   Refractory Chronic Cough Interventions:   Drug: Nalbuphine Hydrochloride;   Drug: Placebo Sponsor:   Trevi Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials